Human Vaccines & Immunotherapeutics Welcoming Your Research!

Special Issue on HPV Vaccines and Associated Cancers

Human Vaccines & Immunotherapeutics

Cancers caused by the human papillomavirus (HPV) continue to be a health concern globally, both for males and females. Despite the existence, availability and demonstrated safety of HPV vaccines, vaccine uptake remains low, and this may be due to varying factors in different parts of the world. For example, while HPV-associated head and neck cancer is a growing concern in the United States and other developed nations, cervical cancer remains a leading cause of cancer deaths among women in the developing countries of the world. And while HPV vaccine coverage may have reached 80% or more in Australia, Rwanda and few other countries, the rates in the United States hover around 60%, well below the Healthy People 2020 targeted rate.

We are primarily interested in data-driven, original research and meta-analyses that answer questions related to HPV, HPV vaccines, and HPV-associated cancers. However, high quality systematic and narrative review articles, as well as commentaries that explore new science and future directions may be accepted, based on journal priorities.

You can contact the Acquisitions Editor Adam Weiss, PhD at adam.c.weiss@taylorandfrancis.com for more information.

Submission Instructions

Please note that submissions will be subject to standard peer-review as indicated in our Instructions for Authors page. The page also outlines detailed instructions on preparing your manuscript.

We invite you to submit a manuscript to this issue here. Please indicate the submission to the Special Issue in your Cover Letter.

Editorial information

  • Guest Editor: Gregory Zimet, PhD, FSAHM, of Indiana University
  • Guest Editor: Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES, Saint Louis University